Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancers

Reuters2026/08/04 13:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Silexion Therapeutics reported new preclinical results for SIL204, extending earlier findings disclosed in May 2026.
Studies indicated SIL204 may make KRAS-mutant pancreatic cancer and NSCLC cells more vulnerable to immune attack, supporting combination use with PD-(L)1 therapies.
The update comes as SIL204 advances into Phase 2/3 evaluation, following initiation of the first clinical trial site in late July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040915PRIMZONEFULLFEED1001255855) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancers

You may also like

Crypto prices